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Abstract: Background: Colorectal cancer (CRC) is a common and potentially preventable malignancy.
Evidence has emerged that coronary artery disease patients are at increased risk for developing
CRC by shared risk factors. Here we investigated an association between CRC and atrial fibrillation
(AF), a surrogate marker of cardiovascular risk, in the setting of routine screening colonoscopy.
Methods: We investigated 1949 asymptomatic participants (median age 61 [54–67] years, 49% females)
undergoing screening colonoscopy within the SAKKOPI registry (Salzburg Colon Cancer Prevention
Initiative). Forty-six participants with AF (2.4%) were identified, and colonoscopy findings were
compared to non-AF participants. Propensity Score Matching (PSM) was used to create 1:1 and 3:1
age- and gender-matched couples. Results: Abnormal findings on screening colonoscopy (any form
of adenoma or carcinoma) were more common in AF participants with an odds ratios (OR) of
2.4 [1.3–4.3] in the unmatched analysis, and 2.6 [1.1–6.3] and 2.0 [1.1–4.0] in the 1:1 and 3:1 matched
groups, respectively. Correspondingly, the odds of finding advanced adenomas or carcinomas was
elevated about three-fold across the different matched and unmatched analyses (OR 3.3 [1.1–10.8]
for 3:1 matched participants). At the same time, the prevalence and number of colonic lesions were
significantly higher in AF participants (63.0% vs. 33.4% for 3:1 matched participants, p < 0.001).
Non-CRC related findings on colonoscopy, like diverticulosis, were non-different between groups.
Conclusion: Participants with AF had a higher burden of advanced premalignant adenomas and
CRC in routine colonoscopy screening. Our data suggest that practitioners should monitor the CRC
screening status, especially in AF patients.
Keywords: atrial fibrillation; colorectal cancer; screening; prevention
1. Introduction
Colorectal cancer (CRC) has a high burden of disease. It accounts for about 12% of all cancer-related
deaths in Europe, corresponding to 3% of all-cause mortality or about 150,000 annual deaths (source:
Eurostat, data for 2015, last update 17 October 2018) [1]. CRC continues to rank as the second (male)
and third (female) most common cause of death from cancer across developed countries. While male
sex and increasing age are common risk factors for CRC worldwide, its prevalence is highest in Western
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countries and historically low in Africa and South-Central Asia. This reflects the contribution of
risk factors, including the consumption of red/processed meat and alcohol, overweight and physical
inactivity, and smoking. While CRC incidence is increasing in some countries due to the adoption
of a more Western lifestyle associated with the above-mentioned risk factors (e.g., Israel and Eastern
Europe [2]), mortality is decreasing in other countries due to the reduction of risk factors, improved
treatment modalities, and CRC screening allowing the removal of premalignant adenomas [3,4]. It has
been calculated that, among these three factors, CRC screening has had the largest effect, explaining
53% of the mortality reduction between 1976 and 2000 [4]. While different approaches are utilized
for CRC screening, including an immunochemical and a guaiac-based fecal occult blood test (FOBT),
fecal DNA tests, computed tomography colonoscopy, and double-contrast barium enema, colonoscopy
is accepted as the gold standard screening method in the United States and Europe [5,6].
Similar to CRC, atrial fibrillation (AF) is a widespread disease in the Western world, being the
most common heart rhythm disorder in adults affecting about 2–3% of the general population in
Europe [7] and more than 33 million patients worldwide [8]. Although there is an inherited component
to the development of atrial fibrillation, particularly in young patients with “lone AF”, AF often
occurs secondary to structural changes of the atria that are caused by other forms of cardiovascular
disease. Hence, cardiovascular risk factors such as obesity, arterial hypertension, diabetes mellitus,
and smoking are also associated with the development of AF [9].
Recently, it has been acknowledged that CRC and cardiovascular diseases, particularly coronary
artery disease, share several risk factors [10]. We previously demonstrated that cardiovascular risk
factors and the presence of coronary artery disease correlate with the detection of colorectal neoplasms
on screening colonoscopy [11]. In the current study, we aimed to investigate whether participants with
AF have an increased risk of colorectal neoplasms on screening colonoscopy.
2. Methods
2.1. Subjects
Participants free of gastrointestinal symptoms were recruited through the screening program at the
Department of Internal Medicine, Oberndorf (Teaching Hospital of the Paracelsus Medical University
Salzburg, Austria) between 2010 and 2014 [11]. Ethical approval for the SAKKOPI registry (Salzburg
Colon Cancer Prevention Initiative) was given by the local ethics committee (Ethikkommission des
Landes Salzburg, approval no. 415-E/1262/2-2010). All consecutive patients aged 45–79 years were
included, with no exclusion criteria. The screening was performed as indicated by national screening
recommendations [12], and informed consent was obtained from all participants.
2.2. Patient Assessment
Study participants were examined twice: blood collection after overnight fasting and physical
examination on day 1, screening colonoscopy on day 2. A detailed medical history was obtained
from every participant, including the current medical regimen and the presence of cardiovascular
comorbidities. Cardiovascular risk was assessed by calculating the Heart Score of the European Society
of Cardiology (ESC) [13] based on current cholesterol levels and blood pressure as well as demographic
variables. The ESC Heart Score estimates the 10-year risk of cardiovascular death.
Participants with AF were identified based on their current reported medication (Figure 1).
If participants where on oral anticoagulation (OAC) or had an increased international normalized
ratio (INR), further information was gathered from healthcare providers regarding the underlying
condition, including review of their ECG. This way, AF participants were separated from those on
OAC for pulmonary embolism or deep vein thrombosis (DVT). In addition, INR was measured in each
participant to identify participants who possibly fail to report OAC, but actually, take OAC for AF
or other conditions. Since non-vitamin K oral anticoagulants were only scarcely available in Austria
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at the time that the cohort was screened, most patients were taking Acenocoumarol (SintromR) or
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Figure 1. Patient Inclusion. In this retrospective study, 1949 participants in a CRC (colorectal cancer) 
screening program were included. Participants with AF (atrial fibrillation) were identified by 
investigation of detailed medical records those individuals under treatment with OAC (oral 
anticoagulation) and with elevated INR (international normalized ratio). This resulted in a cohort of 
46 patients with AF, which were matched with 46 (1:1) and 138 (3:1) non-AF participants utilizing 
age- and gender-based propensity scores. 
Colonoscopic findings were classified as tubular adenoma, advanced adenoma (i.e., villous or 
tubulovillous features, size ≥ 1 cm or high-grade dysplasia, AN) or carcinoma (CRC; colorectal 
cancer) after a combined analysis of macroscopic and histological results [14,15]. Only the 
highest-scoring lesion was counted to allocate patients. We defined the presence of any form of 
adenoma up to carcinoma as an abnormal finding. Hyperplastic polyps per se were not classified as 
abnormal but were investigated separately. Consequently, a normal colonoscopy was defined as the 
absence of adenoma and carcinoma. 
2.3. Propensity Score Matching and Statistical Analysis 
We used SPSS version 25 (IBM) for data management and statistical calculations. For 
comparison of categorical variables, we used a contingency χ2 test. Linear variables were compared 
between groups using the nonparametric Mann–Whitney U-test. A p < 0.05 was accepted as 
statistically significant, and values were given as median [interquartile range] or n (percentage). We 
estimated odds ratios (ORs) with 95% confidence intervals (CI) by univariate logistic regression 
analysis. Haldane–Anscombe correction was used for calculation of odds ratios in small frequency 
samples when an event did not occur in one of the groups. 
We used propensity score matching (PSM) to create a non-AF participant group that resembles 
the demographic characteristics of the AF subpopulation since significant differences in 
demographic parameters between AF participants and the remaining population were identified. 
We used logistic regression analysis in the entire cohort to calculate a predicted probability 
(propensity score) and controlled for age and sex. Thereafter, AF participants were randomly 
matched in a 1:1 and 3:1 ratio to non-AF participants with equal propensity scores (acceptable 
differences <0.01). 
3. Results 
3.1. Study Population and Cardiovascular Risk 
Our screening population included a total number of 1949 participants (median age 61 years, 
49% female, see Table 1 for demographic details). Of these, 73 participants reported being on OAC, 
and 60 participants were found to have INR-elevations >1.2 (Figure 1). Based on the in-detail review 
Figure 1. Patient Inclusion. In this retrospective study, 1949 participants in a CRC (colorectal
cancer) screening program were included. Participants with AF (atrial fibrillation) were identified
by investigation of detailed medical records those individuals under treatment with OAC (oral
anticoagulation) and with elevated INR (international normalized ratio). This resulted in a cohort of
46 patients with AF, which were matched with 46 (1:1) and 138 (3:1) non-AF participants utilizing age-
and gender-based propensity scores.
Colonoscopic findings were classified as tubular adenoma, advanced adenoma (i.e., villous or
tubulovillous features, size ≥ 1 cm or high-grade dysplasia, AN) or carcinoma (CRC; colorectal cancer)
after a combined analysis of macroscopic and histological results [14,15]. Only the highest-scoring
lesion was counted to allocate patients. We defined the presence of any form of adenoma up to
carcinoma as an abnormal finding. Hyperplastic polyps per se were not classified as abnormal but
were investigated separately. Consequently, a normal colonoscopy was defined as the absence of
adenoma and carcinoma.
2.3. Propensity Score Matching and Statistical Analysis
We used SPSS version 25 (IBM) for data management and statistical calculations. For comparison
of categorical variables, we used a contingency χ2 test. Linear variables were compared between groups
using the nonparametric Mann–Whitney U-test. A p < 0.05 was accepted as statistically significant,
and values were given as median [interquartile range] or n (percentage). We estimated odds ratios
(ORs) with 95% confidence intervals (CI) by univariate logistic regression analysis. Haldane–Anscombe
correction was used for calculation of odds ratios in small frequency samples when an event did not
occur in one of the groups.
We used propensity score matching (PSM) to create a non-AF participant group that resembles
the demographic characteristics of the AF subpopulation since significant differences in demographic
parameters between AF participants and the remaining population were identified. We used logistic
regression analysis in the entire cohort to calculate a predicted probability (propensity score) and
controlled for age and sex. Thereafter, AF participants were randomly matched in a 1:1 and 3:1 ratio to
non-AF participants with equal propensity scores (acceptable differences <0.01).
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3. Results
3.1. Study Population and Cardiovascular Risk
Our screening population included a total number of 1949 participants (median age 61 years,
49% female, see Table 1 for demographic details). Of these, 73 participants reported being on OAC,
and 60 participants were found to have INR-elevations >1.2 (Figure 1). Based on the in-detail review
of the participant histories, including ECG (electrocardiogram), 46 participants (2.4%) were found to
have a history of AF. Among these, there were no cases of valvular AF (i.e., moderate to severe mitral
stenosis or mitral valve prosthesis), and their age ranged between 57 and 79 years (median 72 years).
The remaining participants on OAC were treated either for deep vein thrombosis (DVT) or pulmonary
embolism, or had spontaneous INR elevations. The demographics for participants in the AF group
were significantly different from the general population in several aspects: AF participants were
predominantly male and older (Table 1). Concordantly, clinical cardiovascular risk factors (e.g., diabetes
mellitus and arterial hypertension) were more common, and risk scores were significantly higher in AF
participants compared to the rest of the unmatched screening population. Hence, propensity scoring
was performed to match participants based on age and sex in a 1:1 and 3:1 ratio (corresponding to
46 and 138 matched non-AF participants, respectively). After matching, the demographic parameters
were found to be non-different between AF and non-AF participants (Table 1).
Compared to the unmatched population, AF participants had significantly higher cardiovascular
risk as assessed by the ESC Heart score. Also, manifested cardiovascular disease and comorbidities
were significantly more common (coronary artery disease, arterial hypertension, diabetes) in AF
participants. After PSM, diabetes and coronary artery disease continued to be more prevalent in the
AF group. Assessment of overall cardiovascular risk by the ESC Heart Score; however, demonstrated
an increased 10-year risk estimate in the matched non-AF groups compared to AF participants.
3.2. CRC Screening Results
Overall, abnormal findings on screening colonoscopy were found in 28.4% of participants.
Compared to non-AF participants, this prevalence was significantly higher in participants with AF
(47.8%, Table 2). The odds ratio for abnormal screening colonoscopy in the AF group was 2.4 [1.3–4.3]
compared to all non-AF participants which were 2.6 [1.1–6.3] compared to the 1:1 matched group and
2.0 [1.1–4.0] compared to the 3:1 matched group (Figure 2). This difference was mainly driven by the
significantly increased finding of carcinomas with/without advanced adenomas. The odds of finding
carcinoma in AF participants was 18.0 times higher when compared to all non-AF participants and
9.8/6.5 times higher when compared to a 1:1/3:1 PSM-matched group of non-AF participants.
While there was a significant difference in the number of tubular and borderline significant
difference in the finding of advanced adenomas between the AF and unmatched non-AF groups,
these differences were abolished by matching (Supplementary Table S1). On the other side, we found a
significantly increased prevalence of colonic lesions upon screening colonoscopy in AF participants:
while 67.4–73.9% of non-AF participants were free of any colonic lesion, depending on the type of
matching, only 37.0% of AF participants were free of colonic lesions on colonoscopy (Supplementary
Table S1). Diverticulosis was more common, of higher severity, and extending further in the colon
in AF-participants compared to the unmatched group of non-AF participants (Supplementary Table
S1). However, after matching, we did not observe any differences in the prevalence or severity of
diverticulosis between AF and non-AF groups (Supplementary Table S1).
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Table 1. Demographics and Cardiovascular Risk Factors.
All Participants Non-AF Group AF Group Statistical ComparisonAF vs. Non-AF
Unmatched 1:1 Matched 3:1 Matched Unmatched 1:1 Matched 3:1 Matched
PARTICIPANTS 1949 1903 46 138 46
Female 957 (49.1%) 948 (49.8%) 9 (19.6%) 28 (20.3%) 9 (19.6%) p < 0.001 p = 1 p = 0.915
Age (years) 61 [54–67] 60 [5–67] 72 [68–75] 72 [68–75] 72 [68–75] p < 0.001 p = 1 p = 0.955
Range 46–79 46–79 57–79 57–79 57–79
BMI (kg/m2) 26.8 [24.1–29.8] 26.7 [24.1–29.8] 26.4 [24.3–29.4] 27.1 [24.9–30.3] 27.8 [24.0–30.4] p = 0.264 p = 0.276 p = 0.984
COMORBIDITIES
ESC SCORE 0.02 [0.01–0.05] 0.02 [0.01–0.05] 0.07 [0.05–0.11] 0.07 [0.04–0.10] 0.05 [0.03–0.09] p < 0.001 p = 0.039 p = 0.047
Coronary Artery
Disease 112 (6%) 99 (5%) 5 (11%) 20 (14.5%) 13 (28%) p < 0.001 p = 0.036 p = 0.035
Diabetes Mellitus 303 (16%) 282 (15%) 9 (20%) 26 (21.8%) 21 (46%) p < 0.001 p = 0.008 p < 0.001
Arterial Hypertension 1237 (64%) 1224 (65%) 34 (74%) 104 (75.4%) 29 (63%) p = 0.864 p = 0.262 p = 0.106
Smoking
Ever
Current
545 (48%)
192 (17%)
533 (48%)
189 (17%)
22 (48%)
5 (11%)
55 (39.9%)
14 (10.1%)
14 (31%)
6 (13%)
p = 0.085
p = 0.333
p = 0.087
p = 0.748
p = 0.253
p = 0.584
Comparison of baseline participant characteristics for the AF (atrial fibrillation) and the non-AF groups, including an unmatched as well as 1:1 and 3:1 propensity score matched groups.
The numbers are given as a number (percentage) or median [interquartile range]. The level of significance was set to 0.05 and significant differences were marked bold.
Table 2. Colonoscopy Results.
All Participants Non-AF Group AF Group Statistical ComparisonAF vs. Non-AF
Unmatched 1:1 Matched 3:1 Matched Unmatched 1:1Matched
3:1
Matched
Number of
Participants 1949 1903 46 138 46 - - -
CRC Screening Results
Normal Colonoscopy 1395 (71.6%) 1371 (72.1%) 34 (73.9%) 95 (68.8%) 24 (52.2%) 0.003 0.031 0.041
Tubular Adenoma 503 (25.8%) 487 (25.6%) 12 (26.1%) 40 (29.0%) 16 (34.8%) 0.160 0.365 0.459
Advanced Adenoma 81 (4.2%) 79 (4.2%) 0 4 (2.9%) 2 (4.3%) 0.948 0.153 0.632
Carcinoma 14 (0.7%) 10 (0.5%) 0 2 (1:4%) 4 (8.7%) <0.001 0.041 0.017
Adv. Adenoma &
Carcinoma combined 93 (4.8%) 87 (4.6%) 0 6 (4.3%) 6 (13.3%) 0.008 0.013 0.039
The numbers are given as a number (percentage). The level of significance was set to 0.05 and significant differences are marked in bold.
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Figure 2. CRC (colorectal cancer) Screening Results. Comparing AF (atrial fibri lation) and non-AF
participants (A unmatched, B 1:1 matched and C 3:1 matched), o ds ratios for a normal colonoscopy,
tubular adenoma (benign), advanced adenoma (premalignant), and carcinoma were calculated.
The odds ratio for a combine endp int of advanced adenoma and carcinom w s calculated because
of its clinical significance. While normal col noscopy was more significantly co mon in non-AF
controls, there was a significantly increased risk of advanced neopl sias in AF participants across
all comparisons.
4. Discussion
In this study, we report a higher prevalence of advanced colorectal adenomas and carcinomas in
patients with atrial fibrillation undergoing screening colonoscopy.
4.1. Study Population and Matching
To the best of our knowledge, this study is the first to describe an increased prevalence of abnormal
findings on screening colonoscopy in AF participants. The reported prevalence of AF in this study
(2.4%) corresponds well with previously published numbers for the same age group in Germany
(2.5%) [16]. AF participants had significantly different demographics from the rest of the screening
population in this study (male gender and older age); therefore, we used propensity score matching
(PSM) to create a comparable subgroup of non-AF participants. While we did not hypothesize a
direct (causal) relationship between AF and CRC, it was our intention to investigate whether AF
would be associated with abnormal findings on CRC screening, because it is a surrogate parameter for
global cardiovascular risk. Hence, we did not include other markers of cardiovascular risk, including
established risk scores (e.g., ESC Heart Score) or other forms of manifested cardiovascular disease
(e.g., coronary artery disease) in the propensity score. After matching, AF participants were found to
have a lower risk of cardiovascular mortality as estimated by the ESC Heart Score in comparison to
the matched non-AF groups. Hence, we conclude that matching based on age and gender was only
sufficient to correct for major risk factors of heart disease in this cohort. Furthermore, the prevalence
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and severity of diverticular disease of the colon, an incidental finding on screening colonoscopy,
was found to be equivalent between groups (Supplementary Table S1). This finding highlights the
good overall matching of participants in our study. While the presence of diverticulosis is also strongly
age- and gender-dependent, it is also influenced by cardiovascular risk factors that cumulated by a
Western way of living [17].
4.2. Obstacles to CRC Screening in AF Patients
While it is widely accepted that the implementation of a CRC screening program reduces the
burden of CRC, there is still controversy regarding the ideal way of screening (FOBT vs. colonoscopy).
In AF patients, both screening methods are faced with additional concern—while colonoscopy is
a routine procedure with a minimal rate of adverse events, especially in the setting of an elective
screening procedure, the risk of gastrointestinal events (bleeding and perforation) is significantly
increased in AF patients [18]. This can be partially explained by most AF patients being on oral
anticoagulation agents. Although clinical practice guidelines have been published [19,20], physicians
are still concerned about the ideal peri-procedural anticoagulation in the individual patient that
minimizes both the risk of peri-procedural stroke and bleeding complications. It has been shown
that, especially non-cardiologists, perform excessive bridging with low molecular weight heparin [21],
particularly in patients at low cardioembolic risk, which is associated with an increased risk of
bleeding [22]. On the other side, anticoagulation may interfere with CRC screening by FOBT, resulting
in increased [23–26] or reduced [25] positive predictive value of the screening. In our study, none of the
screened patients underwent FOBT screening prior to endoscopy, and symptomatic subjects with prior
rectal bleeding were excluded so that a strictly asymptomatic cohort was investigated in this study.
4.3. Causality
It is relatively easy to name plausible reasons why cancer patients have an increased risk of
developing AF or being diagnosed with AF, especially during the initial period after diagnosis; surgical,
as well as medical treatment may trigger new-onset AF as patients are under extensive medical
surveillance/monitoring during this period of their life [27,28]. It is more difficult to explain the
reverse relationship: why would AF patients have a higher rate of cancer? This finding of our study
is in line with previously published data from Denmark [29], from the Women’s Health Study [30]
and the Explorys platform [31], which have shown an increased rate of overall cancer diagnoses
in new-onset AF patients. Possible explanations include increased detection due to above-average
medical surveillance or bleeding from cancer if under anticoagulation, as well as unknown systemic
or genetic factors and increased susceptibility to symptoms by the individual patient [32]. However,
shared risk factors are most likely to explain this association.
4.4. AF—an Indicator of Lifestyle Associated Disease
While lone or familial AF in young and otherwise healthy patients is a rarity, several risk factors
for AF have been identified. In addition to the “classical” risk factors, higher age and male sex, evidence
has emerged that the development of AF is strongly associated with lifestyle factors. Current and
former smoking increases the risk of developing AF by a factor of 1.5 [33], while a 1-unit increase of
BMI (body mass index) elevates the risk to have AF by 4% [34]. On the other side, weight loss has been
demonstrated to reduce long-term freedom from AF (A Long-Term Follow-Up Study: the LEGACY
study) [35] and the progression of AF (PREVEntion and regReSsive Effect of weight-loss and risk factor
modification on Atrial Fibrillation: the REVERSE-AF study [36]. In addition, cardiorespiratory fitness
training has been demonstrated to further reduce the burden and symptom severity in overweight
AF patients beyond the effect of weight loss (Impact of CARDIOrespiratory FITness on Arrhythmia
Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study) [37]. Similar
to arterial hypertension, AF can be seen as an indicator of lifestyle-associated cardiovascular risk.
Although the rates of smoking and arterial hypertension were not different between AF patients and
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matched non-AF participants in our cohort, a higher presence of coronary artery disease and diabetes
mellitus (and AF itself) demonstrated a true difference in cardiovascular risk between both groups.
At the same time, the risk of developing CRC is highly modified by lifestyle: smoking and obesity
increase the risk of developing CRC by approximately 20%, while high physical activity is protective
according to a meta-analysis of >25,000 CRC patients [38]. Although this study is not able to prove
the hypothesis of a causal relationship between lifestyle, atrial fibrillation, and colorectal cancer risk,
our data highlight the importance of a generalist and interdisciplinary approach towards AF as a
surrogate parameter for general health risk factors, contributing to cardiovascular disease, as well as
colorectal cancer. Although there may be a hesitancy to perform a colonoscopy in AF patients under
oral anticoagulation, our observations demonstrate the importance of CRC screening, particularly in
this patient population at increased risk for malignancies. While we would not recommend screening
AF patients outside of the established screening guidelines, general practitioners and cardiologists
should monitor this population at risk for adequate CRC screening.
5. Limitations
Given the relatively low prevalence of AF in the general population, the present study included
only a relatively small number of AF participants despite screening almost 2000 individuals by
colonoscopy. Further information from larger datasets is certainly warranted to confirm the findings of
this study. Since we did not ask for AF specifically in the questionnaire that was handed out prior to
colonoscopy, our identification is based on a retrospective analysis of participants taking OAC and
having abnormal INR values. Hence, we may have missed individuals that have failed to report being
on OAC with normal INR values and those with AF and low stroke risk scores not under anticoagulant
treatment. Due to the presence of asymptomatic, incidental AF, however, the latter limitation also
applies to prospective studies comparing AF and non-AF populations.
Our study includes only individuals undergoing a screening for colonoscopy. Hence, symptomatic
patients (with anemia, melena, stool abnormalities) are not included in the population, and we can
only speculate about a potential association between AF and CRC in these patients. While we assume
an association between AF, CRC and lifestyle parameters as a common source, our analysis did not
include lifestyle parameters beyond weight/BMI and smoking history.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/7/1083/s1,
Table S1: Additional Findings on Colonoscopy.
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